KARYOPHARM THERAP.DL-0001 financial statements, including revenue, expenses, profit, and loss
The total revenue of 25K for the last quarter is 30.58 M EUR, and it's 10.24% lower compared to the previous quarter. The net income of Q4 23 is -37.90 M EUR.